Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $6.4 million.
- Contineum Therapeutics' Total Current Liabilities rose 955.91% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 955.91%. This contributed to the annual value of $10.0 million for FY2024, which is 8187.45% up from last year.
- As of Q3 2025, Contineum Therapeutics' Total Current Liabilities stood at $6.4 million, which was up 955.91% from $7.2 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Total Current Liabilities registered a high of $10.0 million during Q4 2024, and its lowest value of $3.7 million during Q2 2024.
- Moreover, its 3-year median value for Total Current Liabilities was $6.3 million (2024), whereas its average is $6.7 million.
- Over the last 5 years, Contineum Therapeutics' Total Current Liabilities had its largest YoY gain of 9293.93% in 2025, and its largest YoY loss of 955.91% in 2025.
- Over the past 3 years, Contineum Therapeutics' Total Current Liabilities (Quarter) stood at $5.5 million in 2023, then soared by 81.87% to $10.0 million in 2024, then crashed by 36.22% to $6.4 million in 2025.
- Its Total Current Liabilities stands at $6.4 million for Q3 2025, versus $7.2 million for Q2 2025 and $8.9 million for Q1 2025.